Features of the treatment of patients with type 2 diabetes mellitus and morbid obesity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data on possible unresolved problems of hypoglycemic therapy in patients with type 2 diabetes mellitus and morbid obesity. Currently, there are no clinical guidelines for patients of this specific group, and large randomized clinical trials to study hypoglycemic therapy either do not include patients with morbid obesity, or do not consider them separately in analyses. The modern approaches to the treatment of morbid obesity and diabetes mellitus, as well as the effect of the prescribed hypoglycemic therapy on body weight are analyzed. The necessity of selection of hypoglycemic therapy, which does not have an additional effect on the increase in body weight in patients of this group, is emphasized. Special attention is paid to comorbid conditions and mortality among patients with type 2 diabetes mellitus and morbid obesity.

Full Text

Restricted Access

About the authors

M. V Amosova

Sechenov First Moscow State Medical University (Sechenov University)

Department of Endocrinology №1 of the N.V. Sklifosovsky Institute of Clinical Medicine

O. Yu Gurova

Sechenov First Moscow State Medical University (Sechenov University)

Department of Endocrinology №1 of the N.V. Sklifosovsky Institute of Clinical Medicine

Valentin V. Fadeev

Sechenov First Moscow State Medical University (Sechenov University)

Email: walfad@mail.ru
Dr. Sci. (Med.), Professor, Corr. Member of RAS, Head of the Department and Director of the Clinic of Endocrinology

References

  1. URL: https://www.who.int/ru/news-room/fact-shee ts/detail/diabetes
  2. Farag Y.M., Gaballa M.R. Diabesity: an overvew of a rising epidemic. Nephrol Dial Transplant. 2011;26(1):28-35. doi: 10.1093/ndt/gfq576
  3. Lau D.C., Teoh H. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes. Can J Diabetes. 2015;39(5): S148-S154. doi: 10.1016/j.jcjd.2015.09.090
  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.doi: 10.1016/S0140-6736(98)07019-6.
  5. Barte J.C.M., Ter Bogt N.C.W., Bogers R.P. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obesity Reviews. 2010;11(12):899-906. doi: 10.1111/j.1467-789X.2010.00740.x.
  6. Вознесенская Т.Г. Типология нарушений пищевого поведения и эмоционально-личностные расстройства при ожирении и их коррекция. В. кн.: Ожирение: этиология, патогенез, клинические аспекты. Под ред. И.И. Дедова, Г.А. Мельниченко. М.: МИА, 2006. C. 234-71.
  7. Miller W, Koceja D., Hamilton E. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes. 1997;21:941-47.
  8. Powers PS. Conservative treatment for morbid obesity. In: M. Deitel. Surgery for the morbidly obese patient. Philadelphia - London, 1989. P 27-37.
  9. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL - Primary Health Care Trial Diabetes. Obes Metab. 2005;7:21-27.
  10. Curfman G., Morrissey S., Drazen J. Sibutramine - another flawed diet pill. N Engl J Med. 2010;363:972-74. Doi: 10.1056/ NEJMe1007993.
  11. Ryan D.H., Johnson W.D., Myers V.H., et al. Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study. Arch Intern Med. 2010;170(2):146-54. Doi: 10.1001/ archinternmed.2009.508.
  12. Pi-Sunyer X., Astrup A, Fujioka K., et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373( 1 ):1 1-22. Doi: 10.1056/ NEJMoa1411892.
  13. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых: 3 пересмотр. Ожирение и метаболизм. 2018;15(1):53-70.
  14. Седов В.М., Фишман М.Б. Использование внутрижелудочного баллона при лечении больных с ожирением. Вестник хирургии им. И.И. Грекова. 2008;167(1):33-36.
  15. Brethauer S., et al. Risks and benefits of bariatric surgery: current evidence. Cleveland Clin J. Med. 2006;73(11):993-1007.
  16. Buchwald H., Estok R., Fahrbach K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J. Med. 2009;122:249-61. Doi: 10.1016/j. amjmed.2008.09.041.
  17. Pories W., Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis. 2009;5(2):285-88. Doi: 10.1016/j. soard.2008.12.006.
  18. Arterburn D., Bogart A., Coleman K.J., et al. Comparative effectiveness of bariatric surgery vs. nonsurgical treatment of type 2 diabetes among severely obese adults. Obes Res Clin Pract. 2013;7(4):e258-e268. Doi:10.1016/j. orcp.2012.08.196.
  19. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J. Intern Med 2013;273(3):219-34. doi: 10.1111/joim.12012.
  20. Шихирман Э.В. Ближайшие и отдаленные результаты хирургического лечения ожирения. Дисс. докт. мед. наук. 2017.
  21. Yki-Jarvinen H., Kauppila M., Kujansuu E., et al. Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus. N. Engl J. Med. 1992;327(20):1426-33.
  22. Orme M.E., Nguyen H., Lu J.Y., Thomas S.A. Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. Diabetes Metab Syndr Obes. 2017;10:111-22. Doi: W.2147/DMSO.S1168W.
  23. Li Z., Zhang Y., Quan X., et al. Efficacy and Acceptability of Glycemic Control of GlucagonLike Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network MetaAnalysis. PLoS One. 2016;11(5):e0154206. doi: 10.1371/journal.pone.0154206.
  24. Du Q., Wang Y.J., Yang S., et al. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2014;31(11):1182-95. doi: 10.1007/s12325-014-0164-2.
  25. Charbonnel B., Bertolini M., Tinahones F.J., et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J. Diabetes Complications. 2014;28(6):880-86. doi: 10.1016/j.jdiacomp.2014.07.007.
  26. Shmidt L.J., Habacher W., Augustin T., et al. A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. Diabet Obes Metab. 2014;16(9):769- 79. Doi: 10.1111/ dom.12269.
  27. Maiorino M.I., Chiodini P., Bellastella G., et al. The good companions: insulin and glucagonlike peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabet Res Clin Pract. 2019;154:101-15. Doi: 10.1016/j. diabres.2019.06.009.
  28. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J. Endocrinol. 2009;160(6):909-17. doi: 10.1530/EJE-09-0101.
  29. Maiorino M.I., Chiodini P., Bellastella G., et al. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017;40(4):614-24. doi: 10.2337/dc16-1957.
  30. Castellana M., Cignarelli A., Brescia F., et al. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35(1):e3082. doi: 10.1002/dmrr.3082.
  31. Sun F., Chai S., Li L., et al. Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Diabetes Technology and Therapeutics. 2015;17(1):35-42. Doi: 10.1089/ dia.2014.0188.
  32. Duflou J., et al. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130:306-13.
  33. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет. 2017;20(1S):1-121.
  34. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox and impact of weight loss. J. Am Coll Cardiol. 2009;53(21):1925-32. Doi: 10.1016/j. jacc.2008.12.068.
  35. Uretsky S., Messerli F.H., Bangalore S., et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J. Med. 2007;120(10):863- 70.
  36. Look AHEAD Research Group, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring, Md.). 2006;14(5):737 52. doi: 10.1038/oby.2006.84
  37. Holman R.R., Paul S.K., Bethel M.A., et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89. doi: 10.1056/NEJMoa0806470.
  38. Sjostrom L., Peltonen M., Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65. doi: 10.1001/jama.2011.1914.
  39. Plecka Ostlund M., Marsk R., Rasmussen F., et al. Morbidity and mortality before and after bariatric surgery for morbid obesity compared with the general population. Br J Surg. 2011;98(6):811 16. doi: 10.1002/bjs.7416
  40. Gaede P, Lund-Andersen H., Parving H.-H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. Doi: 10.1056/ NEJMoa0706245
  41. James W., Caterson I., Coutinho W., et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med. 2010;363:905-17. Doi: 10.1056/ NEJMoa1003114
  42. Scheen A.J. Sibutramine on cardiovascular outcome. Diabetes Care. 2011;34(Suppl 2):S114-S119. doi: 10.2337/dc11-s205

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies